Cefpirome. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy in the treatment of severe nosocomial infections and febrile neutropenia

Drugs

Volumn 54, Issue 1, 1997, Pages 117-140

  Wiseman, Lynda R ^a   Lamb, Harriet M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; CEFPIROME; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; PEFLOXACIN; PENICILLIN G; PIPERACILLIN;

ABDOMINAL PAIN; ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONSTIPATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG STABILITY; ENTEROBACTERIACEAE; FEVER; HEADACHE; HOSPITAL INFECTION; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; NEUTROPENIA; NONHUMAN; PHLEBITIS; PLASMID; PNEUMONIA; RASH; REVIEW; SEPTICEMIA; STAPHYLOCOCCUS; STREPTOCOCCUS PNEUMONIAE; TASTE DISORDER; THROMBOPHLEBITIS; VERTIGO; VOMITING;

ENTEROBACTERIACEAE; POSIBACTERIA; STAPHYLOCOCCI; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0030813901     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199754010-00013     Document Type: Review

References (134)

1. Jones RN, Baquero F, Priviteru G, et al. Inducible β-lactamase-mediated resistance to third-generation cephalosporins. Clin Microbiol Infect 1997 Apr; 3 Suppl. 1: S7-S20
2. Bryskier A. New concepts in the field ot cephalosporins: C-3′ quaternary ammonium cephems (Group IV). Clin Microbiol Infect 1997 Apr; 3 Suppl. 1: S1-61
3. Jones RN, Pfaller MA, Allen SD, et al. Antimicrobial activity of cefpirome. An update compared to five third-generation cephalosporins against nearly 6000 recent clinical isolates from five medical centers. Diagn Microbiol Infect Dis 1991 Jul-Aug; 14: 361-4
4. Verhist L. Epidemiology and sensitivity of 8625 ICU and hematology/oncology bacterial isolates in Europe. Scand J Infect Dis 1993; Suppl. 91: 14-24
5. Hanaki H, Akagi H, Masaru Y, et al. TOC-39, a novel parenteral broad-spectrum cephalosporin with excellent activity against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1995 May; 39: 1120-6
6. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing; fifth informational supplement. NCCLS Document M100-S5 (ISBN 1-56238-249-7). Villanova (PA): NCCLS, 1994
7. Clarke AM. Zemcov SJV, Hubinette MM. Comparative in vitro activity of FK-037, a new cephalosporin antibiotic. Diagn Microbiol Infect Dis 1994 Sep; 20: 27-32
8. Martínez-Beltrán J, Cantón R, Liñares J, et al. Multicentre comparative study on the antibacterial activity of FK-037, a new parentend cephalosporin. Eur J Clin Microbiol Infect Dis 1995 Mar; 14: 244-52
9. Jones RN, Barry AL, Thornsberry C. Cefpirome (HR810) disk diffusion susceptibility tests: confirmation of interpretive criteria using cefotaxime and cefoperazone-resistant strains and effects of blood supplemented media. Diagn Microbiol Infect Dis 1986 Apr; 4: 345-9
10. King A, Boothman C, Phillips I. Comparative in vitro activity of cefpirome and cefepime, two new cephalosporins. Eur J Clin Microbiol Infect Dis 1990 Sep; 9: 677-85
11. Bergeron MG, Bernier M. Bactericidal activity of cefpirome (HR 810) against 513 gram-negative bacteria isolated from blood of septicemic patients. Infection 1994 Jul-Aug; 22: 299-305
12. Pelloux I, Le Noc P, Bryskier A, et al. In vitro activity of cefpirome and five other cephalosporins against 326 enteric pathogen isolates [abstract no. E48]. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1994 Oct 4-7: Orlando (TX), 52
13. Mine Y, Watanabe Y, Sakamoto H, et al. In vitro antibacterial activity of FK037, a novel parenteral broad-spectrum cephalosporin. J Antibiot Tokyo 1993 Jan; 46: 71-87
14. Spencer RC. Cross-susceptibility of cefpirome and four other beta-lactams against isolates from haematology/oncology and intensive care units. Scand J Infect Dis 1993; Suppl. 91: 25-32
15. Reeves DS, Bywater MJ, Holt HA. The activity of cefpirome and ten other antibacterial agents against 2858 clinical isolates collected from 20 centres. J Antimicrob Chemother 1993 Mar; 31: 345-62
16. Sapico FL, Ginunas VJ, Montgomerie JZ, et al. Cefpirome, alone and in combination with gentamicin for enterococcal pyelonephritis in the rodent model. Diagn Microbiol Infect Dis 1991 Jul-Aug; 14: 297-300
17. Toye BW, Scriver SR, Low DE, et al. Canadian survey of antimicrobial resistance in Klebsiella spp. and Enterobacter spp. J Antimicrob Chemother 1993 Nov; 32 Suppl. B: 81-6
18. Iwahi T, Okonogi K, Yamazaki T, et al. In vitro and in vivo activities of SCE-2787, a new parenteral cephalosporin with a broad antibacterial spectrum. Antimicrob Agents Chemother 1992 Jul; 36: 1358-66
19. Sader HS, Jones RN. In vitro antimicrobial activity of cefpirome against ceftazidime-resistant isolates from two multicenter studies. Eur J Clin Microbiol Infect Dis 1994 Aug; 13: 675-9
20. Watanabe N-A, Hiruma R, Katsu K. In vitro evaluation of E1077. a new cephalosporin with a broad antibacterial spectrum. Antimicrob Agents Chemother 1992 Mar; 36: 589-97
21. Fung-Tome J, Huczko E, Kolek B, et al. In vitro activities of cefepime alone and with amikacin against aminoglycoside-resistant gram-negative bacteria. Antimicrob Agents Chemother 1991 Dec; 35: 2652-4
22. Fu KP, Foleno BD, Lafredo SC, et al. In vitro and in vivo antibacterial activities of FK037, a novel parenteral broad-spectrum cephalosporin. Antimicrob Agents Chemother 1993 Feb; 37: 301-7
23. Nishino T, Otsuki M, Hatano K. In vitro and in vivo antibacterial activites of FK037, a new parenteral cephalosporin. Chemotherapy Basel 1994 May-Jun; 40: 167-82
24. Inoue K, Inoue E, Mitsuhashi S. In vitro antibacterial activities of FK037: a new parenteral cephalosporin. Chemotherapy Basel 1995 Jul-Aug; 41: 257-66
25. Wise R, Andrews JM, Thornber D. The in-vitro activity of FK-037, a new broad spectrum injectable cephalosporin. J Antimicrob Chemother 1994 Nov; 34: 629-37
26. Neu HC, Chin NX, Labthavikul P. The in vitro activity and beta-lactamase stability of cefpirome (HR 810), a pyridine cephalosporin agent active against staphylococci, Enterobacteriaceae and Pseudomonas aeruginosa. Infection 1985 May-Jun; 13: 146-55
27. Thabaut A, Meyran M, Labia R. Comparative in-vitro activities of cefpirome and 7 other beta-lactam antibiotics against 1981 isolates of Pseudomonas aeruginosa [abstract no. 1023]. 18th International Congress of Chemotherapy: 1993 Jun 27-Jul 2: Stockholm, 293
28. Watanube N-A, Hiruma R, Katsu K. Comparative in-vitro activities ot newer cephalosporins cefclidin, cefepime, and cefpirome against ceftazidime- or imipenem-resistant Pseudomonas aeruginosa. J Antimicrob Chemother 1992 Nov; 30: 633-41
29. Balteh AL, Smith RP, Ritz W. Comparative antimicrobial activity of FK037, cefpirome, ceftazidime and cefepime against aminoglycoside-sensitive and aminoglycoside-resistant Pseudomonas aeruginosa and Pseudomonas spp. Chemotherapy Basel 1994 Nov-Dec; 40: 391-8
30. Shuh PM, Knothe H. The in vitro activity of flomoxef compared to four other cephalosporins and imipenem. Infection 1991; 19 Suppl. 5: S279-83
31. Cheng AFB, Ling TKW, Lam AW. The antimicrobial activity and β-lactamase stability of cefpirome, a new fourth-generation cephalosporin in comparison with other agents. J Antimicrob Chemother 1993 May; 31: 699-709
32. James PA, Hossain FK, Lewis DA, et al. β-lactam susceptibility of Haemophilus influezae strains showing reduced susceptibility to cefuroxime. J Antimicrob Chemother 1993 Aug; 32: 239-46
33. Qadri SMH, Ueno Y, Saldin H, et al. Cefpirome (HR 810), a new cephalosporin: an in vitro investigation. Drug Invest 1992; 4 (6): 535-41
34. Erwin ME, Jones RN, Barrett MS, et al. In vitro evaluation of GR69153, a novel catechol-substituted cephalosporin. Antimicrob Agents Chemother 1991 May; 35: 929-37
35. Hata K, Otsuki M, Nishino T. In vitro and in vivo antibacterial activities of E1077, a novel parenteral cephalosporin with a broad antibacterial spectrum. Antimicrob Agents Chemother 1992 Sep; 36: 1894-901
36. Mine Y, Watanabe Y, Sakamoto H, et al. Excellent activity of FK037, a novel parenteral broad-spectrum cephalosporin, against methicillin-resistant staphyhlococci. J Antibiot Tokyo 1993 Jan; 46: 99-119
37. Di Modugno E, Erbetti I, Ferrari L, et al. In vitro activity of the tribactam GV 104326 against gram-positive, gram-negative, and anaerobic bacteria. Antimicrob Agents Chemother 1994 Oct; 38: 2362-8
38. Jones RN, Barrett MS, Erwin ME. In-vitro activity of FK-037, a new parenteral cephalosporin. J Antimicrob Chemother 1994 Jan; 33: 137-44
39. Raymond J, Vedel G, Bergeret M. In vitro bactericidal activity of cefpirome in combination with vancomycin against methicillin susceptible and methicillin resistant strains of Staphylococcus [abstract]. 8th European Congress of Clinical Microbiology and Infectious Diseases; 1997 May 25-28; Lausanne
40. Drugeon HB, Caillon J, Juvin ME, et al. Bactericidal activity of cefpirome-fosfomycin in comparison with cefolaximefosfomycin against Staphylococcus aureus [abstract no. 256]. 17th International Congress on Chemotherapy; 1991 Jun 23-28; Berlin
41. Wilcox MH, Winstanley TG, Douglas CW, et al. Susceptibility of α-haemolytic streptococci causing endocarditis to benzylpenicillin and ten cephalosporins. J Antimicrob Chemother 1993 Jul; 32: 63-9
42. Barry AL, Brown SD, Novick WJ. In vitro activities of cefotaxime, ceftriaxone, ceftazidime, cefpirome, and penicillin against Streptococcus pneumoniae isolates. Antimicrob Agents Chemother 1995 Oct; 39: 2193-6
43. Fitoussi F, Doit C, Sandin A, et al. Killing activity of cefpirome against penicillin-resistant Streptococcus pneumoniae isolates from patients with meningitis in a pharmacodynamic model simulating the cerebrospinal fluid concentration profile. Antimicrob Agents Chemother 1995 Nov; 39: 2560-3
44. Yoshida R, Kaku M, Kohno S, et al. Trends in antimicrobial resistance of Streptococcus pneumoniae in Japan. Antimicrob Agents Chemother 1995 May; 39: 1196-8
45. Spangler SK, Jacobs MR, Appelbaum PC. Susceptibilities of 177 penicillin-susceptible and -resistant pneumococci to FK-037, cefpirome, cefepime, ceftriaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem, and vancomycin. Antimicrob Agents Chemother 1994 Apr; 38: 898-900
46. Lin̄ares J, Alonso T, Pérez JL, et al. Decreased susceptibility of penicillin-resistant pneumococci to twenty-four β-lactam antibiotics. J Antimicrob Chemother 1992 Sep; 30: 279-88
47. Mason Jr EO, Kaplan SL, Lamberth LB, et al. Increased rate of isolation of penicillin-resistant Streptococcus pneumoniae in a children's hospital and in vitro susceptibilities to antibiotics of potential therapeutic use [see comments]. Antimicrob Agents Chemother 1992 Aug; 36: 1703-7
48. Frémaux A, Sissia G, Bryskier A, et al. In vitro activity of cefpirome and six other parenteral beta-lactam agents against penicillin-susceptible and penicillin-resistant pneumococci [abstract]. 7th European Congress of Clinical Microbiology and Infectious Diseases; 1995 Mar 26-30: Vienna, 59-60
49. Klugman KP, Capper T. In vitro activity of cefpirome against penicillin-resistant pneumococci and its synergistic combination with vancomycin [abstract]. 7th European Congress of Clinical Microbiology and Infectious Diseases; 1995 Mar 26-30: Vienna, 17
50. Marton A, Major P. In vitro susceptibility of Streptococcus pneumoniae strains to nine β-lactam antibiotics and the killing kinetics of cephalosporins alone and in combination with vancomycin or gentamicin. Microb Drug Resis 1996; 2 (3): 361-9
51. Frémaux A, Sissia G, Spicq C, et al. In vitro activity of cefpirome against Streptococcus pneumoniae strains with decreased susceptibility to cefotaxime (abstract). 8th European Congress of Clinical Microbiology and Infectious Diseases; 1997 May 25-28; Lausanne
52. Klugman K, Goldstein F, Kohno S, et al. The role of fourth-generation cephalosporins in the treatment of infections caused by penicillin-resistant streptococci. Clin Microbiol Infect 1997 Apr; 3 Suppl. 1: S48-60
53. Bajak-Souzian S, Visalli MA, Jacobs MR, et al. Antipneumococcal activity of cefpirome and cefotaxime, alone and in combination with vancomycin or teicoplanin [abstract no. E29]. 36th Interscience on Antimicrobial Agents and Chemotherapy; 1996 Sep 15-18; New Orleans (LA)
54. Buschelman BJ, Jones RN, Bale MJ. Effects of blood medium supplements on activities of newer cephalosporins tested against enterococci. J Clin Microbiol 1994 Feb; 32: 565-7
55. Kato N, Kato H, Tanaka Y, et al. In vitro activity of FK037, a new parenteral cephalosporin, against anaerobic bacteria Antimicrob Agents Chemother 1993 May; 37: 957-61
56. Murakami K, Miyazaki S, Kaneko Y, et al. Antibacterial activity of biapenem, a new carbapenem [in Japanese]. Chemotherapy Tokyo 1994 Dec: 42 Suppl. 4: 37-54
57. Mine Y, Watanahe Y, Sakamoto H, et al. In vivo antibacterial activity of FK037, a novel parenteral broad-spectrum cephalosporin. J Antibiot Tokyo 1993 Jan; 46: 88-98
58. Toyosawa T, Miyazaki S, Tsuji A, et al. In vitro and in vivo antibacterial activities of E1077, a novel parenteral cephalosporin. Antimicrob Agents Chemother 1993 Jan; 37: 60-6
59. Klesel N, Isert D, Limbert M, et al. Comparative effects of cefpirome (HR 810) and other cephalosporins on experimentally induced pneumonia in mice. J Antibiol Tokyo 1986 Jul; 39: 971-7
60. Tauber MG, Hackbarth CJ, Scott KG, et al. New cephalosporins cefotaxime. cefpimizole, BMY 28142, and HR 810 in experimental pneumococcal meningitis in rabbits. Antimicrob Agents Chemother 1985 Mar; 27: 340-2
61. Bellido F, Pechère J-C, Hancock REW. Novel method for measurement of outer membrane permeability to new β-lactams in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991 Jan; 35: 68-72
62. Nikaido H, Liu W, Rosenberg EY. Outer membrane permeability and beta-lactamase stability of dipolar ionic cephalosporins containing methoxyimino substituents. Antimicrob Agents Chemother 1990 Feb; 34: 337-42
63. Maejima T, Inoue M, Mitsuhashi S. In vitro antibacterial activity of KP-736, a new cephem antibiotic. Antimicrob Agents Chemother 1991 Jan; 35: 104-10
64. Pucci MJ, Boice-Sowek J, Kessler RE, et al. Comparison of cefepime, cefpirome, and cefaclidine binding affinities for penicillin-binding proteins in Escherichia coli K-12 and Pseudomonas aeruginosa SC8329. Antimicrob Agents Chemother 1991 Nov; 35: 2312-7
65. Piddock LJV, Traynor KA, Griggs DJ. Activity of cefpirome combined with β-lactamase inhibitors and affinity for the penicillin-inding proteins of methicillin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 1992 Apr; 11: 364-71
66. Masuda N, Sakagawa E, Ohya S. Outer membrane proteins responsible for multiple drug resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995 Mar; 39: 645-9
67. Chen HY, Livermore DM. Activity of cefepime and other β-lactam antibioties against permeability mutants of Escherichia coli and Klebsiella pneumoniae. J Antimicrob Chemother 1993 Nov; 32 Suppl. B: 63-74
68. Sanders CC. In vitro activity of fourth generation cephalosporins against Enterobacteriaceae producing extended-spectrum β-lactamases. J Chemother 1996; 8: 57-62
69. Jones RN, Erwin ME. In vitro evaluation of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents Chemother 1992 Jan; 36: 233-8
70. Bercion R, Meyran M, Labia R, et al. Comparative activities of 15 beta-lactam antibioties against 590 strains of Klebsiella pneumoniae according to the production of beta-lactamase [in French]. Pathol Biol Paris 1991 May; 39: 353-60
71. Tzouvelekis LS, Tzelepi E, Mentis AF, et al. In vitro activity of cefpirome against selected clinical enterobacterial isolates with beta-lactamase-mediated resistance. Infection 1995 Nov-Dec; 23: 384-8
72. Pechère JC, Wilson W, Neu H. Laboratory assessment-of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins. J Antimicrob Chemother 1995 Nov; 36: 757-71
73. Bonfiglio G, Stefani S, Nicoletti G. In vitro activity of cefpirome against beta-lactamase-inducible and stably derepressed Enterobacteriaceae. Chemotherapy Basel 1994 Sep-Oct; 40: 311-6
74. Piddock LJV, Traynor EA. β-lactamase expression and outer membrane protein changes in cefpirome-resistant and ceftazidime-resistant Gram-negative bacteria. J Antimicrob Chemother 1991 Aug; 28: 209-19
75. Fung-Tomc JC, Gradelski E, Huczko E, et al. Differences in the resistant variants of Enterobacter cloacae selected by extended-spectrum cephalosporins. Antimicrob Agents Chemother 1996 May; 40: 1289-93
76. Michéa-Hamzehpour M, Kahr A, Pechère J-C. In vitro stepwise selection of resistance to quinolones, β-lactams and amikacin in nosocomial gram-negative bacilli. Infection 1994; 22 Suppl. 2: S105-10
77. Buscher KH, Cullmann W, Dick W, et al. Selection frequency of resistant variants by various β-lactam antibiotics in clinical Enterobacter cloacae isolates, Chemotherapy 1987; 33: 40-51
78. Gradelski E, Fung-Tomc J, Huczko E, et al. Development of resistance in Pseudomonas aeruginosa to broad-spectrum cephalosporins via step-wise mutations. J Antimicrob Chemother 1993 Nov; 32 Suppl. B: 75-80
79. Maass L, Malerczyk V, Verho M. Pharmacokinetics of cefpirome (HR 810), a new cephalosporin derivative administered intramuscularly and intravenously to healthy volunteers. Infection 1987 May-Jun; 15: 207-10
80. Maass L, Malerczyk V, Verho M, et al. Dose linearity testing of intravenous cefpirome (HR 810), a novel cephalosporin derivate. Infection 1987 May-Jun; 15: 202-6
81. Badian M, Malerczyk V, Collins JD, et al. Safety, tolerance and pharmacokinetics of 2.0 g cefpirome (HR 810) after single and multiple dosing. Chemotherapy 1988; 34: 367-73
82. Kavi J, Andrews JM, Ashby JP, et al. Pharmacokinetics and tissue penetration of cefpirome, a new cephalosporin. J Antimicrob Chemother 1988 Dec; 22: 911-6
83. Malerczyk V, Maass L, Verho M, et al. Single and multiple dose pharmacokinetics of intravenous cefpirome (HR 810), a novel cephalosporin derivative. Infection 1987 May-Jun; 15: 211-4
84. Meyer BH, Muller FO, Luus HG, et al. Safety, tolerance and pharmacokinetics of cefpirome administered intramuscularly to healthy subjects. J Antimicrob Chemother 1992 Apr; 29 Suppl. A: 63-70
85. Nakayama I, Akieda Y, Yamaji E, et al. Single- and multiple-dose pharmacokinetics of intravenous cefpirome (HR810) to healthy volunteers. J Clin Pharmacol 1992 Mar; 32: 256-66
86. Tabata S, Shimura T, Maeda T, et al. Protein binding of cefpirome sulfate in man and animals and its displacing effect on bilirubin bound to human serum albumin [in Japanese]. Chemotherapy Tokyo 1991 Feb; 39 Suppl. 1: 109-14
87. Wise R. Tissue penetration of the fourth generation parenteral cephalosporins. J Chemother 1996; 8 Suppl. 2: 63-72
88. Giamarellou H, Kuvouklis E, Pedikaris G, et al. Aqueous humor (AH) levels of cefpirome (CPO) after IV administration, in humans [abstract no. A17]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15-18: New Orleans (LA), 4
89. Baldwin DR, Maxwell SRJ, Honeybourne D, et al. The penetration of cefpirome into the potential sites of pulmonary infection. J Antimicrob Chemother 1991 Jul; 28: 79-86
90. Wolff M, Chavanet P, Kazmierczak A, et al. Diffusion of cefpirome into the cerebrospinal fluid of patients with purulent meningitis. J Antimicrob Chemother 1992 Apr; 29 Suppl. A: 59-62
91. Chavanet P, Pechinot A, Waldner-Combernoux A, et al. Meningeal diffusion of cefpirome in adults [in French]. Pathol Biol Paris 1989 May; 37: 442-5
92. Nix DE, Wilton JH, Velasquez N, et al. Cerebrospinal fluid penetration of cefpirome in patients with non-inflamed meninges. J Antimicrob Chemother 1992 Apr; 29 Suppl. A: 51-7
93. Saxby MF, Arkell DG, Andrews JM, et al. Penetration of cefpirome into prostalic tissue [letter]. J Antimicrob Chemother 1990 Mar; 25: 488-90
94. Lameire N, Malerczyk V, Drees B, et al. Single-dose pharmacokinetics of cefpirome in patients with renal impairment. Clin Pharmacol Ther 1992 Jul; 52: 24-30
95. Ogata Y, Suzuki H, Saruta T. Pharmacokinetics of cefpirome (CPR) in patients with impaired renal function [in Japanese]. Kansenshogaku Zasshi 1991 Dec; 65: 1514-8
96. Wilcox MH, Pithie A, Smith G, et al. Relationship between cefpirome clearance, serum creatinine, weight and age in patients treated for infection. J Antimicrob Chemother 1991 Aug; 28: 291-9
97. Veys N, Lameire N, Malerczyk V, et al. Single-dose pharmacokinetics of cefpirome in patients receiving hemodialysis and in patients treated by continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 1993 Oct; 54: 395-401
98. Hasegawa H, Shimizu K, Sakaguchi M, et al. Pharmacokinetics of cefpirome in patients undergoing continuous ambulatory peritoneal dialysis [abstract no. 4074]. Can J Infect Dis 1995; 6: 447C
99. Taugourdeau MC, Hagege H, Laurent-Puig P, et al. Pharmacokinetics of cefpirome in patients with cirrhosis and ascites [abstract no. 746]. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy 1992 Oct 11-14; Anaheim (CA), 235
100. Nahata MC, Barson WJ, Puri SK. Pharmacokinetics of cefpirome in pediatric patients. Antimicrob Agents Chemother 1995; 39: 2348-9
101. Kearns GL, Weber W, Harnisch L, et al. Single-dose pharmacokinetics of cefpirome in paediatric patients. Clin Drug Invest 1995 Aug; 10: 71-85
102. Saez-Llorens X, Aujard Y, Gallardo P, et al. Pharmacokinetics of cefpirome in neonates [abstract no. A69]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15-18; New Orleans (LA), 14
103. Craig WA. The pharmacokinetics of cefpirome - rationale for a twelve-hour dosing regimen. Scand J Infect Dis 1993; Suppl. 91: 33-40
104. Collins J, Badian M, Lehr KH, et al. Multiple dose pharmacokinetics of 2 g cefpirome i.v. in young and elderly volunteers [abstract no. 1219]. 29th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1989; Washington DC, 308
105. Naide Y, Hibi H, Kumamoto Y, et al. Dose-finding study of HR 810 (cefpirome) in complicated urinary tract infections [in Japanese]. Chemotherapy Tokyo 1991 Feb; 39: 158-73
106. Naide Y, Kumamoto Y, Hirose T, et al. Comparative study of cefpirome and ceftazidime in complicated urinary tract infections [in Japanese]. Hinyokika Kiyo 1991 Apr; 37: 447-64
107. Norrby SR. Cefpirome: efficacy in the treatment of urinary and respiratory tract infections and safety profile. Scand J Infect Dis 1993; Suppl. 91: 41-50
108. Norrby SR, Dictar B, et al. Cefpirome versus ceftazidime in the treatment of urinary tract infections. J Antimicrob Chemother 1992 Apr; 29 Suppl. A: 95-104
109. Carbon C, Gonzalez OR, Dictar M, et al. Prospective randomized phase II study of intravenous cefpirome 1g or 2g bd in the treatment of hospitalized patients with different infections. J Antimicrob Chemother 1992 Apr; 29 Suppl. A: 87-94
110. Soejima R, Sumi M, Hino J, et al. A comparative study between cefpirome and ceftazidime in respiratory tract infections [in Japanese]. Kansenshogaku Zasshi 1991 Apr; 65: 400-22
111. Norrby SR, Dotevall L, Eriksson M, et al. Efficacy and safety of cefpirome (HR810). J Antimicrob Chemother 1988 Oct; 22: 541-7
112. Ishikawa M, Kimura H, Shimizu T, et al. Cefpirome in obstetrics and gynecology [in Japanese]. Chemotherapy Tokyo 1991 Feb; 39 Suppl. 1: 624-32
113. Miller AR, Wilson APR, Adey G, et al. Efficacy and tolerance of cefpirome in the treatment of severe infection in patients in intensive care [abstract]. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1992 Oct 11-14; Anaheim (CA), 373
114. Le Gall JR, Brun-Buisson C, Carlet J, et al. Etude multicentrique du cefpirome en réanimation. Med Mal Infect 1994; 24: 1184-9
115. Wilcox MH, Pithie AD, Welsby PD, et al. Efficacy of cefpirome in the treatment of infection in hospitalised adults [abstract no. 283], 17th International Congress of Chemotherapy; 1991 June 23-28; Berlin: 1991
116. Wolff M, Carbon C, Falissard B, et al. Comparative study of cefpirome (CPO) and ceftazidime (CAZ) in ICU patients with pneumonia [abstract no. LM21]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15-18; New Orleans (LA), 284
117. Norrhy SR, Geddes AM, Shah PM, et al. Cefpirome (CPO) vs ceftazidime (CAZ) as empirical sepsis treatment [abstract no. CE0329]. 20th International Congress of Chemotherapy; 1997 Jun 29-Jul 3; Sydney
118. Reiffers J, Cony MP, Pris J, et al. Efficacy of cefpirome in the initial empirical management of febrile neutropenic patients with hematological malignancies [abstract]. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1992 Oct 11-14; Anaheim (CA), 373
119. Browett P, Schwarer A, Whitby M, et al. Comparison of cefpirome/gentamicin and piperacillin/gentamicin as empirical therapy for neutropenic fever [abstract]; 1997. (Data on file)
120. Open, controlled, randomised, multiclinic, comparative study of the efficacy, safety and tolerance of cefpirome (HR810) versus ceftazidime in the empiric treatment of patients with suspected bacteraemia/sepsis. Hoechst Marion Roussel. HR810/2/MN/302/SP; 1997 Feb 14. (Data on file)
121. Hoechst. Cefpirome Scientific Monograph. Hoechst (Frankfurt). 1996. (Data on file)
122. Legall JR, Leleu G, Orvain J, et al. Efficacy of cefpirome in patients with severe pneumonia [abstract]. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1993 Oct 17-20: New Orleans (LA), 290
123. Norrby SR, Geddes AM. Efficacy of cefpirome in the treatment of septicaemia. Scand J Infect Dis 1993; Suppl. 91: 51-9
124. Hamazaki H, Hasegawa H, Horiuchi A, et al. Clinical evaluation of cefpirome sulfate for severe infections in patients with hematological disorders [in Japanese]. Jpn J Antibiot 1997 Jan; 50 (1): 12-21
125. Schlaeffer F, Brener S, Cohen-Kitzes R. Cefpirome twice daily versus imipenem three times a day for the treatment of soft tissue and skin infections [abstract]. 9th Mediterranean Congress of Chemotherapy; 1994 Jun 12-17; Milan, 101
126. Rubinstein E, Labs R, Reeves A. A review of the adverse events profile of cefpirome. Drug Saf 1993 Nov; 9: 340-5
127. Vincent J-L, Bihari DJ, Suler PM, et al. The prevalence of nosocomial infection in intensive care units in Europe: results of the European prevalence of infection in intensive care study. JAMA 1995; 274: 639-44
128. Committee of the Scientific Assembly on Microbiology. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and prevention strategies: a consensus statement. Am J Respir Crit Care Med 1995; 153: 1711-25
129. Kibbler CC. Neutropenic infections: strategies for empirical therapy. J Antimicrob Chemother 1995 Oct; 36 Suppl. B: 107-17
130. Glauser MP. Monotherapy for the neutropenic patient: a realistic goal? Curr Opin Infect Dis 1994 Oct; 7 Suppl. 1: 11-6
131. Hughes WT, Pizzo PA, Wade JC, et al. Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Clin Infect Dis 1992 Nov; 15 Suppl. 1: S206-15
132. Glauser M, Boogaerts M, Cordonnier C, et al. Empiric therapy of bacterial infections in severe neutropenia. Clin Microbiol Infect 1997 Apr; 3 Suppl. 1: S77-86
133. Bodey GP, Nies BA, Mohberg NR, et al. Imipenem/cilastatin therapy of infections in cancer patients. Cancer 1987; 60: 255-62
134. Sanders JW, Powe NR, Moore RD. Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients; a metaanalysis. J Infect Dis 1991 Nov; 164: 907-16